Stockreport

Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc.  (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview
PDF -- Differentiating Safety and Tolerability Profile of Edasalonexent Through More Than 55 Patient Years of Exposure -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pha [Read more]